Tourmaline Capital Partners, a next-generation real estate firm focused on Class-A office investments throughout the United States, announced its entry into the life sciences sector with the hiring of life sciences real estate executive William (Bill) D. Hunter as president of Tourmaline Life Sciences.
“The market dislocation is just beginning and we think those with technical expertise and capital will have a tremendous investment opportunity given stalled projects, fractured programmatic ventures and an evolving tenant landscape,” said Brandon Huffman, CEO of Tourmaline Capital Partners. “Bill is the perfect fit for our organization given his wealth of experience and depth of technical savvy.”
Hunter boasts a career spanning more than two decades in the life sciences sector, having completed more than $10 billion in acquisitions, including 12 million square feet of leasing and over five million square feet of strategic campus re-positioning projects for major research-driven institutions nationwide. His expertise focuses upon the adaptive re-use and re-purposing of complex infrastructure assets geared towards addressing the comprehensive and nuanced needs of firms throughout the life sciences ecosystem.
Hunter was a pre-IPO founding executive at BioMed Realty Trust (now Blackstone) and Wexford Science + Technology (acquired by BMR, and subsequently sold to Ventas). Prior to joining Tourmaline, Hunter co-founded Thor Life Sciences & Lightstone Life Sciences, both family office-backed life sciences platforms based in NYC.
